A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

NCT05886634 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Dedifferentiated Liposarcoma
Soft Tissue Sarcoma
Sarcoma,Soft Tissue
Sarcoma
Recurrent Dedifferentiated Liposarcoma
Unresectable Dedifferentiated Liposarcoma
Metastatic Dedifferentiated Liposarcoma

Interventions

DRUG: Etrumadenant
DRUG: Zimberelimab

Sponsor

Memorial Sloan Kettering Cancer Center